Radar · Life Sciences in France
Best Life Sciences Companies in France
The 1400 best Life Sciences companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inventiva Pharma.
By Riya SenguptaFinancials
1400companies tracked
$11.8Bdisclosed funding
1unicorns
528have raised
France's Life Sciences sector has pulled in $11.8 billion in disclosed funding across 1,400 tracked companies, and that number alone tells you this is one of Europe's more serious biopharma ecosystems. The global market sits at roughly $167.8 billion with a 10.2% CAGR, and French companies are competing for a real slice of it. Owkin leads the directory at $321 million raised. Sensorion has drawn $205 million. Afyren sits at $97 million, UroMems at $86 million. One unicorn has cleared the threshold. Bpifrance and Sofinnova Partners anchor the investor side, alongside EIC Fund and Idinvest Partners. These aren't seed bets, they're conviction positions.
So what's driving the next wave? Hot themes are gene delivery systems, cell-based therapies, and diagnostic biotechnology, while mRNA capacity expansion signals where infrastructure investment is heading globally. App-layer momentum across health and life sciences is running at roughly 43% median install growth year-over-year, which I'd read as a demand signal, not a distraction. Aging population dynamics and strong job growth are keeping institutional capital interested. If you're mapping the French Life Sciences field by funding weight and momentum, this directory ranks exactly that.
Sources & further reading
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
- Antibiotics API Market Size, Share & Forecast to 2036
- Top 10 Takeover Targets of 2025
FLIAR INTELLIGENCE · LIFE SCIENCES × FRANCE
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
62%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2015median founding year
539kcombined LinkedIn audience
27%of audience held by top 3
8companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in France
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Inventiva Pharma Provider of therapeutic solutions for fibrosis, lysosomal storage disorders and oncology 72Growth top 20%Product top 24%Funding top 26%Market top 40% All 10 signals ▾Growthtop 20% Producttop 24% Fundingtop 26% Markettop 40% Talenttop 41% Innovationtop 43% Fin. healthtop 46% Moattop 48% Techbottom 48% Globalbottom 46% Growth: Revenue +44% YoY · Web rank 10,000,000 → 5,000,000 YoY Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 72/100 | $433M | 20 mo ago | Public | 117 | Frederic Cren CEO & Co-Founder | — | — | 1 award |
| 2 | Owkin 🦄 AI generative biology company to create the new standard of biology reasoning 89AI top 18%Innovation top 21%Patents top 21%Funding top 23% All 12 signals ▾AItop 18% Innovationtop 21% Patentstop 21% Fundingtop 23% Growthtop 23% Moattop 25% Globaltop 34% Fin. healthtop 37% Talenttop 38% Markettop 40% Techtop 46% Newsbottom 27% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Innovation: 49 patents (top 29% of patent-holders) · 39 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 89/100 | $321M | 3 mo ago | Series B | 47 | Gilles Wainrib Co-Founder | — | 25 patents AI-powered medical imaging analysis for cancer prognosis and federated learning networks | 1 launch |
| 3 | Cellectis Developer of cancer immunotherapies based on gene-edited CAR T-cells 64Patents top 20%Funding top 25%Product top 29%Innovation top 30% All 11 signals ▾Patentstop 20% Fundingtop 25% Producttop 29% Innovationtop 30% Newstop 33% Markettop 38% Moattop 41% Globaltop 45% Growthtop 48% Talentbottom 49% Techbottom 46% Patents: 1,579 patents matched (strict assignee match) · 326 filings since 2022 vs 610 in 2017-21 Funding: Raised $267M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $267M | 25 mo ago | Public | 236 | Andre Choulika Chief Executive Officer | 6 signals IPO · Announcements · Earnings | 1,579 patents Patents concentrated in chemistry & materials | — |
| 4 | Sensorion Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in… 62Funding top 11%News top 18%Patents top 20%Innovation top 28% All 11 signals ▾Fundingtop 11% Newstop 18% Patentstop 20% Innovationtop 28% Growthtop 37% Moattop 41% Talenttop 49% Marketbottom 49% Globalbottom 43% Partnersbottom 35% Techbottom 33% Funding: Raised $205M across 4 rounds · 4 rounds over 3 yrs (1.3/yr) News: 10 BI events in 12 mo (of 52 tracked, 8 types) · +67% YoY rank vs industry peers · Fliar Intelligence Index 62/100 | $205M | 4 mo ago | Public | 50 | Nawal Ouzren CEO & Director | 10 signals ▲67% Funding · Leadership · Capital raise | 119 patents Inner ear drug and gene therapies plus cochlear delivery devices for hearing preservation | — |
| 5 | Imcheck Therapeutics Developer of immunotherapeutic antibodies for the treatment of multiple diseases 55Patents top 21%Funding top 24%Moat top 26%Innovation top 27% All 9 signals ▾Patentstop 21% Fundingtop 24% Moattop 26% Innovationtop 27% Markettop 49% Talentbottom 49% Globalbottom 45% Techbottom 30% Newsbottom 27% Patents: 104 patents matched (strict assignee match) · 75 filings since 2022 vs 29 in 2017-21 Funding: Raised $185M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $185M | 21 mo ago | Acquired | 48 | Pierre D'epenoux Chief Executive Officer | — | 104 patents Patents concentrated in chemistry & materials | — |
| 6 | Syremis Developer of novel medicines for mental health conditions 22Funding top 20%Global top 45%Talent bottom 49%Tech bottom 29% All 5 signals ▾Fundingtop 20% Globaltop 45% Talentbottom 49% Techbottom 29% Marketbottom 25% Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 3 countries beyond France rank vs industry peers · Fliar Intelligence Index 22/100 | $165M | 5 mo ago | Series A | — | Elisabeth Kogan Co-Founder & CEO | — | — | — |
| 7 | Enyo Pharma Developer of therapeutics for diseases with impaired kidney function 60Patents top 20%Innovation top 21%Funding top 25%Moat top 26% All 9 signals ▾Patentstop 20% Innovationtop 21% Fundingtop 25% Moattop 26% Growthtop 45% Techbottom 49% Globalbottom 43% Marketbottom 40% Newsbottom 27% Patents: 164 patents matched (strict assignee match) · 114 filings since 2022 vs 50 in 2017-21 Innovation: 164 patents (top 16% of patent-holders) · 114 filings since 2022 vs 50 in 2017-21 rank vs industry peers · Fliar Intelligence Index 60/100 | $113M | 12 mo ago | Series C | 34 | — | — | 164 patents Novel antiviral small‑molecule salts and FXR‑agonist combos for hepatitis D therapy | — |
| 8 | MedinCell Developer of a portfolio of long-acting injectables in various therapeutic areas 76Patents top 13%Product top 14%Innovation top 18%Funding top 23% All 11 signals ▾Patentstop 13% Producttop 14% Innovationtop 18% Fundingtop 23% Growthtop 25% Newstop 31% Moattop 35% Techtop 42% Markettop 45% Globalbottom 43% Talentbottom 41% Patents: 303 patents matched (strict assignee match) · 179 filings since 2022 vs 81 in 2017-21 Product: 9 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 76/100 | $104M | 15 mo ago | Public | 143 | Christophe Douat CEO | 4 signals ▲100% Funding · Leadership | 303 patents Advanced pharmaceutical formulations and targeted drug delivery systems for controlled release. | — |
| 9 | AFYREN Provider of analytical services for microbiology, chemistry and bioprocesses industries 40Funding top 25%Talent top 28%Moat top 35%Patents top 37% All 11 signals ▾Fundingtop 25% Talenttop 28% Moattop 35% Patentstop 37% Techtop 43% Innovationtop 48% Growthtop 48% Newsbottom 49% Globalbottom 40% Marketbottom 32% Fin. healthbottom 20% Funding: Raised $96.9M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $97M | 1 mo ago | Public | 32 | Regis Nouaille Co-Founder | 6 signals ▼50% Capital raise · Earnings | 118 patents Recovery and valorization of potassium salts and metabolites from anaerobic fermentation processes | — |
| 10 | UroMems Developer of active implantable devices for urological incontinence 72Funding top 21%Tech top 25%Patents top 27%Innovation top 28% All 9 signals ▾Fundingtop 21% Techtop 25% Patentstop 27% Innovationtop 28% Moattop 29% Growthtop 35% Globalbottom 43% Marketbottom 42% Newsbottom 22% Funding: Raised $85.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Tech: 33 technologies across 5/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 72/100 | $86M | 1 mo ago | Series D | 49 | — | — | 173 patents Implantable occlusive devices and control systems for sealing anatomical ducts and protecting sensors | 3 job openings · 1 internship |
| 11 | TreeFrog Therapeutics Developer of stem cells and organoids using proprietary technology 62Patents top 21%Innovation top 22%Funding top 26%Moat top 29% All 10 signals ▾Patentstop 21% Innovationtop 22% Fundingtop 26% Moattop 29% Growthtop 35% Markettop 48% Talentbottom 49% Globalbottom 43% Techbottom 25% Newsbottom 22% Patents: 148 patents matched (strict assignee match) · 143 filings since 2022 vs 5 in 2017-21 Innovation: 148 patents (top 18% of patent-holders) · 143 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $84M | 12 mo ago | Series B | 110 | Kevin Alessandri Co-Founder & CTO | — | 148 patents Engineered neural tissue therapeutics and microfluidic cell‑encapsulation platforms for regenerative medicine | 1 launch |
| 12 | AB Science Developer of tyrosine kinase inhibitors for multiple disease indications 42Funding top 20%Patents top 21%Innovation top 28%Moat top 28% All 9 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 28% Moattop 28% Newstop 33% Growthtop 45% Techbottom 41% Globalbottom 38% Marketbottom 21% Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $83M | 1 mo ago | Public | 3 | — | 3 signals ▲200% Earnings · Funding · Capital raise | 461 patents Small-molecule kinase and tubulin inhibitors for oncology and rare disease therapies | — |
| 13 | GenSight Biologics Developer of viral vector-based gene therapies for retinal neurodegenerative diseases 55AI top 15%Product top 19%Funding top 20%Patents top 33% All 11 signals ▾AItop 15% Producttop 19% Fundingtop 20% Patentstop 33% Moattop 38% Innovationtop 43% Globaltop 47% Growthbottom 47% Marketbottom 41% Newsbottom 33% Techbottom 31% AI: Holds AI/ML patents (G06N-family CPC) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 55/100 | $77M | 3 mo ago | Public | 23 | — | — | 89 patents Optogenetic retinal devices and AAV gene‑therapy vectors for vision restoration | 1 award |
| 14 | DBV Technologies Developer of products for the treatment of various kinds of food allergies 57Product top 24%Funding top 31%News top 31%Partners top 31% All 13 signals ▾Producttop 24% Fundingtop 31% Newstop 31% Partnerstop 31% Talenttop 32% Growthtop 38% Markettop 42% Moattop 42% Globaltop 45% Fin. healthtop 45% Techtop 49% Innovationbottom 37% Patentsbottom 31% Product: 2 distinct product lines · Company stage: Public Funding: Raised $68.9M across 7 rounds · 7 rounds over 20 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $69M | 14 mo ago | Public | 88 | Pierre-Henri Benhamou Co-Founder & CEO | 18 signals ▲29% Earnings · Leadership · Funding | 9 patents Transdermal patch platforms for delivering biologics and inducing immune tolerance/allergy desensitization. | 1 job opening · 1 launch · 1 award |
| 15 | Wandercraft Provider of AI-powered exoskeleton solutions 74Innovation top 19%Patents top 22%Moat top 26%Talent top 28% All 13 signals ▾Innovationtop 19% Patentstop 22% Moattop 26% Talenttop 28% Fundingtop 31% Growthtop 35% Producttop 36% AItop 45% Markettop 46% Fin. healthbottom 46% Techbottom 45% Globalbottom 42% Newsbottom 18% Innovation: 132 patents (top 15% of patent-holders) · 78 filings since 2022 vs 41 in 2017-21 Patents: 132 patents matched (strict assignee match) · 78 filings since 2022 vs 41 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $67M | 12 mo ago | Series D | 117 | Alexandre Boulanger Co-Founder | — | 132 patents Powered lower-body exoskeletons with 3‑DOF hip joints and AI‑based gait stabilization | 2 partnerships |
| 16 | Aqemia Provider of an AI and quantum physics to discover therapeutic molecules 60Funding top 28%AI top 30%Moat top 38%Tech top 39% All 11 signals ▾Fundingtop 28% AItop 30% Moattop 38% Techtop 39% Innovationtop 44% Growthtop 48% Patentstop 49% Talentbottom 49% Marketbottom 44% Globalbottom 36% Newsbottom 18% Funding: Raised $62.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 60/100 | $63M | 14 mo ago | Series A | 60 | Maximilien Levesque Founder & CEO | — | 4 patents Small-molecule inhibitors of METTL3 RNA methyltransferase and MAP4K1 kinase for therapeutic use | 1 job opening · 1 award |
| 17 | Eligo Bioscience Developer of in vivo gene editing technology for microbiome modulation 48Patents top 16%Innovation top 19%Moat top 29%Funding top 36% All 11 signals ▾Patentstop 16% Innovationtop 19% Moattop 29% Fundingtop 36% Techtop 48% Talentbottom 49% Growthbottom 48% Globalbottom 44% Marketbottom 42% Fin. healthbottom 27% Newsbottom 22% Patents: 199 patents matched (strict assignee match) · 142 filings since 2022 vs 57 in 2017-21 Innovation: 199 patents (top 13% of patent-holders) · 142 filings since 2022 vs 57 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $52M | 13 mo ago | Series B | 44 | Xavier Duportet Co-Founder & CEO | — | 199 patents Targeted phage-based therapies and diagnostics for Cutibacterium acnes skin disorders | 1 job opening |
| 18 | SafeHeal Developer of a medical device for colorectal surgery 45Funding top 27%Growth top 35%News top 36%Tech top 39% All 9 signals ▾Fundingtop 27% Growthtop 35% Newstop 36% Techtop 39% Moattop 39% Patentsbottom 47% Innovationbottom 44% Globalbottom 43% Marketbottom 30% Funding: Raised $52.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $52M | 9 mo ago | Series C | 16 | — | 3 signals ▲200% Funding | 15 patents Intra‑operative intestinal anastomosis cleaning and protection devices | — |
| 19 | FineHeart Developer of an implantable cardiovascular device for treating heart failures 60Funding top 23%Moat top 26%Growth top 28%Patents top 33% All 9 signals ▾Fundingtop 23% Moattop 26% Growthtop 28% Patentstop 33% Innovationtop 34% Newstop 36% Marketbottom 45% Globalbottom 43% Techbottom 34% Funding: Raised $51.9M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 162 patents rank vs industry peers · Fliar Intelligence Index 60/100 | $52M | 5 mo ago | Series C | 50 | — | 3 signals Funding | 162 patents Implantable cardiac assist devices and transcutaneous power systems for heart support | — |
| 20 | Step Pharma Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment 35Patents top 20%Innovation top 26%Moat top 29%Funding top 31% All 11 signals ▾Patentstop 20% Innovationtop 26% Moattop 29% Fundingtop 31% Newstop 43% Growthtop 45% Techbottom 46% Globalbottom 44% Talentbottom 41% Fin. healthbottom 26% Marketbottom 20% Patents: 109 patents matched (strict assignee match) · 73 filings since 2022 vs 36 in 2017-21 Innovation: 109 patents (top 27% of patent-holders) · 73 filings since 2022 vs 36 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $52M | 3 mo ago | Series C | 12 | Andy Parker President & CEO | — | 109 patents Small-molecule CTPS1/CTPS2 inhibitors for treating proliferative and hematologic cancers | 2 awards |
| 21 | Egle Therapeutics Provider of T cells based therapeutics for oncology and autoimmune diseases 45Funding top 34%Talent top 38%Moat top 39%Patents top 40% All 7 signals ▾Fundingtop 34% Talenttop 38% Moattop 39% Patentstop 40% Innovationbottom 49% Marketbottom 44% Globalbottom 43% Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $47M | 15 mo ago | Series A | 28 | Eliane Piaggio Co-Founder | — | 11 patents Engineered cytokine therapeutics and biomarkers for cancer immunotherapy | — |
| 22 | Coave Therapeutics Developer of gene therapy for ocular and neurological disease 50Funding top 33%Patents top 34%Growth top 35%Moat top 36% All 9 signals ▾Fundingtop 33% Patentstop 34% Growthtop 35% Moattop 36% Innovationtop 42% Talentbottom 49% Techbottom 44% Globalbottom 43% Marketbottom 38% Funding: Raised $44.0M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Patents: 27 patents matched (strict assignee match) · 26 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 17 mo ago | Series B | 34 | Rodolphe Clerval Chief Executive Officer | — | 27 patents Engineered AAV viral vectors with lactam/squaramide capsid modifications for CNS gene therapy | — |
| 23 | Innate Pharma Developer of antibody based therapeutics to treat cancer 76Fin. health top 17%Patents top 21%Funding top 28%Talent top 28% All 11 signals ▾Fin. healthtop 17% Patentstop 21% Fundingtop 28% Talenttop 28% Innovationtop 32% Markettop 34% Moattop 40% Globaltop 48% Techbottom 49% Growthbottom 47% Newsbottom 47% Fin. health: Revenue ~$62.3M (FY2016) · Net margin 23.3% Patents: 1,175 patents matched (strict assignee match) · 266 filings since 2022 vs 455 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $43M | 13 mo ago | Public | 191 | Marc Bonneville Co-Founder | 4 signals ▼60% Earnings · Announcements | 1,175 patents Engineered antibody and cell therapies targeting immune checkpoints and cancer antigens | — |
| 24 | May Health Provider of solution for restoring ovulation in PCOS patients 40Funding top 29%Moat top 29%Growth top 35%Tech top 47% All 7 signals ▾Fundingtop 29% Moattop 29% Growthtop 35% Techtop 47% Newstop 48% Globalbottom 36% Marketbottom 29% Funding: Raised $36.2M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · 1 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 40/100 | $36M | 3 mo ago | Series B | 12 | — | — | — | — |
| 25 | Bioptimus Developer of AI foundation model to transform biological research 64AI top 20%Talent top 23%Funding top 33%Growth top 35% All 9 signals ▾AItop 20% Talenttop 23% Fundingtop 33% Growthtop 35% Moattop 42% Techbottom 49% Globalbottom 38% Marketbottom 36% Newsbottom 18% AI: Classified as an AI company Talent: 6 named leaders on record · 6 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 64/100 | $35M | 17 mo ago | Series A | — | Jean-Philippe Vert Co-Founder | — | — | 2 launchs · 1 partnership |
| 26 | Waiv Developer of AI-powered diagnostic tools for precision oncology and pathology 48Funding top 26%AI top 35%Talent top 38%Global bottom 48% All 6 signals ▾Fundingtop 26% AItop 35% Talenttop 38% Globalbottom 48% Techbottom 45% Marketbottom 31% Funding: Raised $33.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: ai-powered, machine learning rank vs industry peers · Fliar Intelligence Index 48/100 | $33M | 3 mo ago | Series C | — | Lionel Guillou Co-Founder & CTO | — | — | — |
| 27 | Adcytherix Developer of therapeutics for the treatment of cancer 40Growth top 15%News top 22%Funding top 31%Moat top 42% All 8 signals ▾Growthtop 15% Newstop 22% Fundingtop 31% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Techbottom 20% Growth: Fresh capital in last 24 mo News: 6 BI events in 12 mo (of 8 tracked, 3 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $32M | 8 mo ago | Series A | — | Carsten Dehning Co-Founder | 6 signals Funding · Capital raise · Fundraising | — | 1 award |
| 28 | Osivax Developer of vaccines against constantly mutating pathogens 32Growth top 28%Funding top 37%Moat top 37%Patents top 40% All 10 signals ▾Growthtop 28% Fundingtop 37% Moattop 37% Patentstop 40% Innovationtop 49% Globalbottom 45% Techbottom 37% Marketbottom 33% Newsbottom 21% Fin. healthbottom 15% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $31.8M across 8 rounds · 8 rounds over 9 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $32M | 15 mo ago | Series B | 40 | — | — | 16 patents mRNA and protein-based vaccine formulation and delivery technologies | 1 job opening |
| 29 | Phagos Developer of AI-powered bioplatform for targeted bacterial treatments using phages 64Funding top 34%AI top 35%Global top 45%Talent top 45% All 5 signals ▾Fundingtop 34% AItop 35% Globaltop 45% Talenttop 45% Techbottom 45% Funding: Raised $31.6M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) AI: Product described with: ai-powered, artificial intelligence rank vs industry peers · Fliar Intelligence Index 64/100 | $32M | 8 mo ago | Series A | — | Adèle James Co-Founder & CTO | — | — | 1 award |
| 30 | Robeauté Developer of microrobots for neurosurgical applications 35Growth top 35%Talent top 38%Funding top 44%Global bottom 39% All 6 signals ▾Growthtop 35% Talenttop 38% Fundingtop 44% Globalbottom 39% Techbottom 38% Marketbottom 27% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 17 mo ago | Seed | 15 | Joana Cartocci Co-Founder & COO | — | — | — |
| 31 | Nextbiotix Developer of probiotic for the treatment of inflammatory bowel diseases 21Funding top 32%Talent top 35%Moat top 48%News bottom 42% All 7 signals ▾Fundingtop 32% Talenttop 35% Moattop 48% Newsbottom 42% Globalbottom 38% Techbottom 37% Marketbottom 20% Funding: Raised $27.1M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: Analyst team rating 5/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 21/100 | $27M | 7 mo ago | Series A | 8 | Benjamin Hadida CEO & co-Founder | — | — | — |
| 32 | SeqOne Provider of bioinformatics tools for the analysis of genome sequencing data 55Growth top 32%Moat top 37%Funding top 38%Patents top 44% All 10 signals ▾Growthtop 32% Moattop 37% Fundingtop 38% Patentstop 44% Innovationtop 47% Techtop 48% Markettop 50% Talentbottom 49% Globalbottom 36% Newsbottom 20% Growth: Web rank 10,000,000 → 5,000,000 YoY · 1 acquisition/expansion move in 24 mo Moat: Editorial + unicorn rating 6/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 12 mo ago | Series A | 70 | Nicolas Philippe CEO | — | 18 patents Bioinformatics platforms for genomic HRD detection, structural variant identification, and phenotyping support | 1 partnership |
| 33 | Adocia Developer of therapeutics for the treatment of diabetes and obesity 45Product top 14%Patents top 28%Innovation top 35%Funding top 35% All 11 signals ▾Producttop 14% Patentstop 28% Innovationtop 35% Fundingtop 35% Moattop 35% Markettop 49% Growthbottom 47% Techbottom 45% Globalbottom 43% Fin. healthbottom 35% Newsbottom 30% Product: 5 distinct product lines · Company stage: Public Patents: 684 patents matched (strict assignee match) · 119 filings since 2022 vs 272 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $26M | 5 mo ago | Public | 111 | — | — | 684 patents Peptide therapeutics formulation and delivery using polymer conjugates and injectable hydrogels | — |
| 34 | 4Moving Biotech Developer of therapeutics designed to translate scientific research into medicine 42Growth top 28%Moat top 32%Funding top 39%Patents top 40% All 9 signals ▾Growthtop 28% Moattop 32% Fundingtop 39% Patentstop 40% Innovationtop 44% Talentbottom 49% Techbottom 35% Globalbottom 35% Marketbottom 29% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Moat: Editorial + unicorn rating 4/10 · IP moat: 25 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $22M | 4 mo ago | Series B | — | Francis Berenbaum Co-Founder | — | 25 patents Cartilage regeneration therapeutics targeting chondrocyte proliferation and joint disease treatment | — |
| 35 | Chipiron Developer of portable MRI machines 29Moat top 39%Innovation top 40%Funding top 41%Patents top 41% All 10 signals ▾Moattop 39% Innovationtop 40% Fundingtop 41% Patentstop 41% Talentbottom 49% Growthbottom 47% Techbottom 40% Globalbottom 40% Marketbottom 20% Newsbottom 17% Moat: Editorial + unicorn rating 3/10 · IP moat: 22 patents Innovation: 22 patents (top 71% of patent-holders) · 22 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $21M | 13 mo ago | Series A | 7 | Evan Kervella Co-founder & CEO | — | 22 patents Patents concentrated in computing, sensing & instrumentation | — |
| 36 | SquareMind Developer of robotic medical equipment for skin cancer detection 50AI top 15%Patents top 28%Innovation top 32%Moat top 32% All 9 signals ▾AItop 15% Patentstop 28% Innovationtop 32% Moattop 32% Fundingtop 38% Talentbottom 49% Globalbottom 43% Techbottom 41% Marketbottom 26% AI: Holds AI/ML patents (G06N-family CPC) Patents: 57 patents matched (strict assignee match) · 48 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $21M | 1 mo ago | Seed | 10 | Ali Khachlouf Co-Founder & CEO | — | 57 patents Robotic arm guidance systems and AI-driven medical imaging marker generation | — |
| 37 | EG 427 Developer of gene therapies for neurogenic bladder 35Talent top 28%Patents top 37%Funding top 38%Moat top 39% All 9 signals ▾Talenttop 28% Patentstop 37% Fundingtop 38% Moattop 39% Innovationtop 48% Globalbottom 43% Marketbottom 33% Techbottom 33% Newsbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Patents: 17 patents matched (strict assignee match) · 17 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $20M | 15 mo ago | Series B | 17 | Pierre Denys Co-Founder | — | 17 patents HSV‑1 based viral gene‑therapy vectors for neurological and bladder disease treatments | — |
| 38 | VitaDX Early diagnostics for bladder cancer 35Funding top 35%Tech top 44%Moat top 48%Talent bottom 49% All 6 signals ▾Fundingtop 35% Techtop 44% Moattop 48% Talentbottom 49% Globalbottom 38% Marketbottom 36% Funding: Raised $14.4M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Tech: 27 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 35/100 | $14M | 9 mo ago | Series B | 29 | Allan Rodriguez CEO | — | — | — |
| 39 | Tafalgie Developer of therapeutics for the treatment of chronic postoperative and neuropathic pain 24Growth top 35%Funding top 47%Talent bottom 49%Global bottom 29% All 6 signals ▾Growthtop 35% Fundingtop 47% Talentbottom 49% Globalbottom 29% Techbottom 28% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $14.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 9 mo ago | Series A | — | Eric Schettini Founder & President | — | — | 1 award |
| 40 | RDS Developer of wearable sensor devices for monitoring cardiac health 35Innovation top 36%Moat top 38%Patents top 45%Funding top 46% All 8 signals ▾Innovationtop 36% Moattop 38% Patentstop 45% Fundingtop 46% Talentbottom 49% Globalbottom 36% Marketbottom 32% Newsbottom 20% Innovation: 28 patents (top 43% of patent-holders) · Deep-tech classification: Tech Hardware Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $14M | 8 mo ago | Series A | 22 | Elie Lobel CEO | — | 28 patents Wearable vital‑sign and cardiac monitoring technologies for health tracking | 1 award |
| 41 | Lattice Medical Provider of 3D-printed technology for soft tissue reconstruction 32Funding top 31%Growth top 35%Moat top 38%Talent bottom 49% All 7 signals ▾Fundingtop 31% Growthtop 35% Moattop 38% Talentbottom 49% Globalbottom 38% Techbottom 37% Marketbottom 25% Funding: Raised $13.5M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $14M | 7 mo ago | Series B | — | Julien Payen Co-Founder & CEO | — | — | — |
| 42 | Elkedonia Developer of innovative antidepressant treatment, accessible, fast-acting, and free from dependence. 48Talent top 38%Funding top 44%Global top 45% All 3 signals ▾Talenttop 38% Fundingtop 44% Globaltop 45% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $12.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $13M | 12 mo ago | Seed | — | Delphine Charvin CEO & Co-Founder & Director | — | — | 2 awards |
| 43 | Spore Biotechnologies Developer of microbial detection technology for life science industries 53AI top 15%Growth top 35%Talent top 38%Funding top 42% All 10 signals ▾AItop 15% Growthtop 35% Talenttop 38% Fundingtop 42% Moattop 42% Techtop 43% Patentstop 46% Innovationbottom 47% Globalbottom 39% Marketbottom 23% AI: Holds AI/ML patents (G06N-family CPC) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | 5 mo ago | Series A | 5 | Amine Raji Co-Founder & CEO | — | 7 patents Rapid bacterial detection and analysis using spectroscopic and AI-driven diagnostic devices | 1 job opening · 1 award |
| 44 | Seabelife Developer of small-molecule drugs that simultaneously inhibit necroptosis and ferroptosis 37Talent top 28%Growth top 35%Patents top 42%Moat top 42% All 10 signals ▾Talenttop 28% Growthtop 35% Patentstop 42% Moattop 42% Innovationbottom 49% Techbottom 47% Fundingbottom 46% Newsbottom 42% Globalbottom 35% Marketbottom 24% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $6M | 8 mo ago | Seed | 8 | Marie-Therese Dimanche-Boitrel Co-Founder | — | 10 patents Regulated necrosis and ferroptosis inhibition therapeutics for tissue regeneration | — |
| 45 | ErVimmune Developer of immunotherapies for the treatment of cancer 16News top 36%Moat top 38%Funding top 40%Patents top 44% All 9 signals ▾Newstop 36% Moattop 38% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 36% Marketbottom 25% Techbottom 23% News: 3 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 16/100 | $5M | 4 mo ago | Series A | — | Stephane Depil Founder | 3 signals Funding | 9 patents HERV-based cancer epitope discovery and AML diagnostic/therapeutic biomarkers | 1 job opening |
| 46 | Oncodesign Provider of preclinical assessment services for anticancer therapies 55Patents top 34%Product top 36%Moat top 40%Market top 42% All 10 signals ▾Patentstop 34% Producttop 36% Moattop 40% Markettop 42% Fundingtop 43% Innovationtop 44% Growthtop 45% Globaltop 49% Techbottom 47% Newsbottom 27% Patents: 157 patents matched (strict assignee match) · 20 filings since 2022 vs 77 in 2017-21 Product: 2 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 55/100 | $5M | 3 mo ago | Acquired | 238 | — | — | 157 patents Macrocyclic small‑molecule kinase inhibitors for RIP2 and LRRK2 therapeutic targets | — |
| 47 | Lifeaz Developer of connected defibrillators 55Growth top 28%Talent top 28%Tech top 32%Funding top 41% All 10 signals ▾Growthtop 28% Talenttop 28% Techtop 32% Fundingtop 41% Producttop 46% Moattop 47% Marketbottom 47% Patentsbottom 35% Innovationbottom 32% Globalbottom 31% Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 55/100 | $5M | 4 mo ago | Series B | 52 | Martial Itty Co-Founder & CTO | — | 5 patents Portable cardiac defibrillation kits and integrated measurement systems for emergency care | — |
| 48 | Biophytis Developer of drugs for neuromuscular and age-related diseases 45Patents top 32%Moat top 35%Funding top 37%Innovation top 38% All 10 signals ▾Patentstop 32% Moattop 35% Fundingtop 37% Innovationtop 38% Globaltop 45% Partnerstop 45% Newstop 46% Growthbottom 47% Techbottom 43% Marketbottom 42% Patents: 175 patents matched (strict assignee match) · 62 filings since 2022 vs 105 in 2017-21 Moat: Editorial + unicorn rating 5/10 · IP moat: 175 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $3M | 3 mo ago | Public | 24 | — | 5 signals ▼69% Funding · Announcements · Earnings | 175 patents Phytoecdysteroid-based therapeutics for muscle, metabolic, respiratory, and ocular disorders | 1 expansion |
| 49 | Abbelight Provider of solutions for microscopes, reagents, and software for image analysis 57AI top 15%Product top 30%Moat top 32%Innovation top 40% All 9 signals ▾AItop 15% Producttop 30% Moattop 32% Innovationtop 40% Patentstop 40% Fundingtop 42% Techbottom 48% Marketbottom 42% Globalbottom 36% AI: Holds AI/ML patents (G06N-family CPC) Product: 4 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 57/100 | $2M | 5 mo ago | Series B | 42 | — | — | 24 patents Super-resolution single-molecule fluorescence microscopy hardware and image data handling | 2 awards |
| 50 | CTIBiotech Develops 3D human tissue models 19Tech top 45%Talent bottom 49%Funding bottom 47%Global bottom 29% All 5 signals ▾Techtop 45% Talentbottom 49% Fundingbottom 47% Globalbottom 29% Marketbottom 25% Tech: 17 technologies across 5/8 capability areas · Cloud: Amazon Ses, Amazon Web Services Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 19/100 | $1M | 1 mo ago | Funding Raised | — | Nico Forraz CEO | — | — | 2 launchs · 1 partnership · 1 award |
Top 12 Life Sciences companies in France
#1
Owkin 🦄Series B · Paris, Ile de France · founded 2016 · 47 employees$321.1Mraised▾
Owkin 🦄
Series B · Paris, Ile de France · founded 2016 · 47 employees
AI generative biology company to create the new standard of biology reasoning. The company is creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. It is building the operating system for biology a platform in general-purpose biology intelligence.
Fliar Intelligence Index™ 89how this company ranks against its industry peers
AI
top 18%Innovation
top 21%Patents
top 21%Funding
top 23%Growth
top 23%Moat
top 25%AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC)
Innovation: 49 patents (top 29% of patent-holders) · 39 filings since 2022 vs 10 in 2017-21 · Deep-tech classification: Artificial Intelligence
Patents: 49 patents matched (strict assignee match) · 39 filings since 2022 vs 10 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 67k LinkedIn followers — 12.4% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Series B$33M
- Jan 2023Grant (prize money)$216.4K
- Jun 2022Series B$80M
- Nov 2021Series B$180M
Founders & team
Investors
Eight Roads Ventures, F-Prime Capital, Google Ventures, MACSF, Cathay Innovation, Bpifrance
Tech stack
Amazon SesAmazon Web ServicesApple Icloud MailCdnjsCloudflareCloudflare Bot Management
#2
Series D · Grenoble, Auvergne Rhone Alpes · founded 2011 · 49 employees$85.7Mraised▾
Series D · Grenoble, Auvergne Rhone Alpes · founded 2011 · 49 employees
Developer of active implantable devices for urological incontinence. The device MyoElectroMechanical System is based on a technology where a patient‘s activity is measured in real-time through micro-sensors inside the implant into which algorithms are embedded; the system interprets data coming from the micro-sensors and computes the urethral pressure to apply.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 21%Tech
top 25%Patents
top 27%Innovation
top 28%Moat
top 29%Growth
top 35%Funding: Raised $85.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) · Last round Series D (May 2026)
Tech: 33 technologies across 5/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Patents: 173 patents matched (strict assignee match) · 78 filings since 2022 vs 69 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 10k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Antené(e) de Recherche Clinique Senior, Engineering Director Medical Device
Funding rounds
- May 2026Series D$60M
- Jun 2024Series C$47M
- Apr 2021Series B$8.3M
- May 2020Series B$17.5M
Investors
Financiere Arbevel, Wellington Partners Venture Capital, Bpifrance, Supernova Invest, b2venture, CITA
Tech stack
CloudflareCloudflare Bot ManagementComplianzCore-JsElementorGenesis Blocks
#3
Public · Paris, Ile de France · founded 2012 · 32 employees$96.9Mraised▾
Public · Paris, Ile de France · founded 2012 · 32 employees
Provider of analytical services for microbiology, chemistry, and bioprocesses industries. It has developed its product known as Afynerie, technology, which directly valorizes non-food biomass (wastes) into biomolecules of high energetical and chemical interest. The company offers services including the measurement of methane volume (or more generally biogas) produced by degradation of organic substrates by anaerobic microorganisms, & organic substrates physicochemical characterization.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 25%Talent
top 28%Moat
top 35%Patents
top 37%Tech
top 43%Innovation
top 48%Funding: Raised $96.9M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Grant (prize money) (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 5/10 · IP moat: 118 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 20k LinkedIn followers — 3.7% of this cohort's audience
Funding rounds
- Apr 2026Grant (prize money)$3.5M
- Feb 2026Post IPO$8.2M
- Nov 2025Post IPO$26.6M
- Jul 2025Grant (prize money)$4.7M
Founders & team
Investors
JEREMIE AUVERGNE, Valquest Capital Management, Sofinnova Partners, Bpifrance, Kemin, Odyssee Venture
Tech stack
Apache Http ServerComplianzContact Form 7Core-JsDropzoneFormidable Form
#4
Public · Paris, Ile de France · founded 2001 · 3 employees$83.2Mraised▾
Public · Paris, Ile de France · founded 2001 · 3 employees
Developer of tyrosine kinase inhibitors for multiple disease indications. The company's lead candidate drugs are masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer for oncology, neurodegenerative and inflammatory indications.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 28%Moat
top 28%News
top 33%Growth
top 45%Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) · Last round Post IPO (May 2026)
Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 · Latest publication 2025
Innovation: 461 patents (top 5% of patent-holders) · 78 filings since 2022 vs 86 in 2017-21
Funding rounds
- May 2026Post IPO$3M
- Oct 2025Post IPO$3.3M
- Jul 2025Post IPO$2.3M
- May 2025Post IPO$2M
Tech stack
Contact Form 7Core-JsGoogle AnalyticsGoogle Font ApiGsapIsotope
#5
Public · Montpellier, Occitanie · founded 2009 · 50 employees$205.3Mraised▾
Public · Montpellier, Occitanie · founded 2009 · 50 employees
Provider of gene therapies for the treatment and prevention of inner ear disorders to restore hearing in patients. It offers deep research platform aimed at understanding the pathophysiology and causes of inner ear diseases to develop effective therapeutic solutions. It offers SENS-501 a gene therapy for severe hearing loss due to OTOF gene mutations, and GJB2-GT targeting hearing loss from mutations in the GJB2 gene.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 11%News
top 18%Patents
top 20%Innovation
top 28%Growth
top 37%Moat
top 41%Funding: Raised $205M across 4 rounds · 4 rounds over 3 yrs (1.3/yr) · Last round Post IPO (Jan 2026)
News: 10 BI events in 12 mo (of 52 tracked, 8 types) · +67% YoY · 7 high-value events (IPO/M&A/funding/contracts) in 12 mo
Patents: 119 patents matched (strict assignee match) · 63 filings since 2022 vs 41 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 9k LinkedIn followers · 112 engagements/post (2.4× cohort median)
Funding rounds
- Jan 2026Post IPO$95.7M
- Apr 2024Post IPO$16.8M
- Feb 2024Post IPO$54.4M
- Aug 2023Post IPO$38.4M
Founders & team
Investors
Redmile Group, Invus, Sofinnova Partners, Sanofi, Artal Capital, Cormorant Asset Management
Tech stack
BootstrapContact Form 7Core-JsGoogle AnalyticsGoogle Font ApiJquery
#6
Public · Paris, Ile de France · founded 2011 · 23 employees$76.6Mraised▾
Public · Paris, Ile de France · founded 2011 · 23 employees
Developer of viral vector-based gene therapies for retinal neurodegenerative diseases. The company develops innovative approaches to prevent retinal degeneration in selected pathological conditions, to restore vision in patients suffering from very low vision or blindness. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene for the treatment of Leber Hereditary Optic Neuropathy associated with a mutation in the ND4 gene, and GS030 which comprises a gene encoding a photoactivatable channelrhodopsin for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
AI
top 15%Product
top 19%Funding
top 20%Patents
top 33%Moat
top 38%Innovation
top 43%AI: Holds AI/ML patents (G06N-family CPC)
Product: 3 distinct product lines · Company stage: Public
Funding: Raised $76.6M across 9 rounds · 9 rounds over 13 yrs (0.7/yr) · Last round Post IPO (Mar 2026)
Audience (LinkedIn): 10k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2026Post IPO$2M
- Dec 2025Post IPO$3.4M
- Nov 2025Post IPO$2.3M
- Oct 2025Post IPO$4.3M
Investors
Abingworth, Versant Ventures, Index Ventures, Novartis Venture Fund, Fidelity Investments, Jennison
Tech stack
Apache Http ServerGoogle AnalyticsJqueryMediaelement.JsMicrosoft 365Microsoft Advertising
#7
Series A · Paris, Ile de France · founded 2017$165Mraised▾
Series A · Paris, Ile de France · founded 2017
Developer of novel medicines for mental health conditions. The company focuses on neuropsychiatric treatments rooted in clinically validated mechanisms. It advances programs for schizophrenia, psychotic disorders, major depressive disorder, and bipolar depression. The lead program is a dual agonist in Phase 1 development. Another program is a novel antagonist currently in IND-enabling studies.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 20%Global
top 45%Talent
bottom 49%Tech
bottom 29%Market
bottom 25%Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Dec 2025)
Global: Investors from 3 countries beyond France
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum -2 · hiring: Chemistry Lead (R&D), CMCL Lead
Funding rounds
- Dec 2025Series A$165M
Founders & team
Investors
Dexcel, Third Rock Ventures, Bain Capital Life Sciences, Google Ventures, QVT Family Office, Pictet Group
Tech stack
Core-JsElementorGoogle Font ApiHello ElementorJqueryJquery Migrate
#8
Series C · Saint-Genis-Pouilly, Auvergne-Rhone-Alpes · founded 2014 · 12 employees$51.7Mraised▾
Series C · Saint-Genis-Pouilly, Auvergne-Rhone-Alpes · founded 2014 · 12 employees
Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment. The company focuses on creating selective, orally bioavailable drugs for blood cancers and solid tumors. Their lead asset is in clinical development for lymphoma, ovarian cancer, and essential thrombocythaemia. Future development may include treatment regimens for solid tumours.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Patents
top 20%Innovation
top 26%Moat
top 29%Funding
top 31%News
top 43%Growth
top 45%Patents: 109 patents matched (strict assignee match) · 73 filings since 2022 vs 36 in 2017-21 · Latest publication 2026
Innovation: 109 patents (top 27% of patent-holders) · 73 filings since 2022 vs 36 in 2017-21
Moat: Editorial + unicorn rating 7/10 · IP moat: 109 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Feb 2026Grant (prize money)$3M
- Oct 2025Series C$44M
- Mar 2021Series B$41.6M
- Nov 2017Series A$10.1M
Founders & team
Investors
Hadean Ventures, Sunstone, Kurma Partners, Pontifax, Bpifrance, Inserm Transfert Initiative
#9
Series C · Pessac, Nouvelle Aquitaine · founded 2010 · 50 employees$51.9Mraised▾
Series C · Pessac, Nouvelle Aquitaine · founded 2010 · 50 employees
Developer of an implantable cardiovascular device for treating heart failures. The device provides long-term circulatory assistance. The I.C.O.M.S. (Implantable Cardiac Output Management System) is synchronized to heart innate contraction and helps to manage heart failure disease.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 23%Moat
top 26%Growth
top 28%Patents
top 33%Innovation
top 34%News
top 36%Funding: Raised $51.9M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) · Last round Series C (Jan 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 162 patents · Soonicorn
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 8k LinkedIn followers
Funding rounds
- Jan 2026Series C$40.8M
- Jan 2026Grant (prize money)$56M
- Oct 2022Grant (prize money)$2.4M
- 2022Grant (prize money)$19.8M
Investors
Broadview Ventures, Aquiti Gestion, IRDI Soridec Gestion, Galia Gestion, Sofimac Investment Managers, M Capital
Tech stack
CdnjsCloudflareCore-JsElementorElementor Header & Footer BuilderFont Awesome
#10
Series B · Paris, Ile de France · founded 2017 · 12 employees$36.2Mraised▾
Series B · Paris, Ile de France · founded 2017 · 12 employees
Ablacare, now May Health provides a solution for restoring ovulation in patients with polycystic ovary syndrome. It gives a solution for an invasive treatment that is done transvaginally under ultrasound guidance without any anesthesia requirements.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 29%Moat
top 29%Growth
top 35%Tech
top 47%News
top 48%Global
bottom 36%Funding: Raised $36.2M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · 1 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Mar 2026Series B$11.7M
- May 2024Series B$25M
- Jul 2019Series A$11.2M
Investors
Sofinnova Partners, Trill impact, Bpifrance, Avestria Ventures, MD Start, Lifeblood Capital
Tech stack
Alpine.JsCivicthemeCloudflareCloudflare Bot ManagementCookieyesCore-Js
#11
Seed · Paris, Ile de France · founded 2019 · 10 employees$20.6Mraised▾
Seed · Paris, Ile de France · founded 2019 · 10 employees
Developer of robotic medical equipment for skin cancer detection. It offers autonomous robots equipped with third-dimension construction software that capture data by full-body mapping to detect skin cancer. It allow physicians to track the growth of moles on the body using off-the-shelf robots.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
AI
top 15%Patents
top 28%Innovation
top 32%Moat
top 32%Funding
top 38%Talent
bottom 49%AI: Holds AI/ML patents (G06N-family CPC)
Patents: 57 patents matched (strict assignee match) · 48 filings since 2022 vs 9 in 2017-21 · Latest publication 2026
Innovation: 57 patents (top 44% of patent-holders) · 48 filings since 2022 vs 9 in 2017-21 · Deep-tech classification: Tech Hardware
Funding rounds
- Apr 2026Seed$18M
- Jul 2022Grant (prize money)$2.6M
- 2022Grant (prize money)—
- Seed—
Founders & team
Investors
EIC Fund, Europa, Sonder Capital, Bpifrance, Adamed Technology, Teampact Ventures
Tech stack
Amazon Web ServicesHstsLenisNode.JsNuxt.JsOpen Graph
#12
Series C · France · founded 2026$33Mraised▾
Series C · France · founded 2026
Developer of AI-powered diagnostic tools for precision oncology and pathology. It provides clinically validated AI tests to streamline diagnostic workflows and ignite biomarker discovery. The company leverages machine learning, foundation models, pathology, and oncology expertise. It utilizes diverse datasets to reinforce model performance and accelerate clinical translation.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 26%AI
top 35%Talent
top 38%Global
bottom 48%Tech
bottom 45%Market
bottom 31%Funding: Raised $33.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
AI: Product described with: ai-powered, machine learning
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Mar 2026Series C$33M
Founders & team
Investors
OTB Ventures, AIC, Serena, Karista, SISTAFUND
Tech stack
Apple Icloud MailCloudflareCookiebotGoogle AnalyticsGoogle Font ApiGoogle Hosted Libraries
Funding & investor landscape
$11.8Btotal disclosed funding
495companies funded
1,357disclosed rounds
5rounds last 90 days
Most active investors
Notable founders
Gilles Wainrib
Co-Founder · Owkin
Thomas Clozel
Chief Executive Officer and Co-founder · Owkin
Regis Nouaille
Co-Founder · AFYREN
Nicolas Sordet
Founder & CEO · AFYREN
Nawal Ouzren
CEO & Director · Sensorion
Elisabeth Kogan
Co-Founder & CEO · Syremis
Andy Parker
President & CEO · Step Pharma
Ali Khachlouf
Co-Founder & CEO · SquareMind
Lionel Guillou
Co-Founder & CTO · Waiv
Meriem Sefta
Co-Founder & CEO · Waiv
Francis Berenbaum
Co-Founder · 4Moving Biotech
Benjamin Hadida
CEO & co-Founder · Nextbiotix
Prism market signals · France · country-scoped Prism corpus, 2,021,151 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · France
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
research sentiment over time
200820152026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 38% → 41% across 2008–2026.
top research entities
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
leading researchers
Pauline Le Boulch · Anani Amegan Missinou · Stéphanie Boutet · François Perreau · Maria J. Manzanares-Dauleux · Martin Beaumont · Jordi Estellé · Sofia Titah
▲
Breakthroughs337 · 28%
▼ 31%→27% share
▼0.9× share momentum0 median citations80% since 2021mostly empirical
Gene-focused breakthrough research surged from 3 to 26 papers, with Virus, Transcription factor, and Bacteria newly emerging.
rising sub-themes (early→recent)
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
Newly emergingVirus 0→9 · Transcription factor 0→8 · Bacteria 0→7
Landmark Targeting DNA Double-Strand Breaks with TAL Effector Nucleases · 1,987 cites
◆
Advancements418 · 34%
▲ 31%→36% share
▲1.2× share momentum0 median citations86% since 2021mostly empirical
Advancements field-share rose 31%→36%; Transcriptome, Metabolomics, and Microbiome newly emerged alongside Agriculture climbing 1→20.
rising sub-themes (early→recent)
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
Newly emergingTranscriptome 0→13 · Metabolomics 0→12 · Microbiome 0→12
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns221 · 18%
▼ 25%→16% share
▼0.6× share momentum0 median citations74% since 2021mostly empirical
Antibiotic resistance concern papers rose 3→12; Drug resistance and Food security newly flagged as concerns in French biotech research.
rising sub-themes (early→recent)
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Newly emergingFood security 0→8 · Selection (genetic algorithm) 0→8 · Drug resistance 0→6
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · France
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Paris216 · +0.42
Toulouse47 · +0.28
Lyon41 · +0.40
Marseille39 · +0.51
Grenoble20 · +0.56
Strasbourg14 · +0.54
PATENT SIGNAL · France
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
34,222 filings8,000 assigneespeak 3751/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Centre NAT RECH Scient10056
- INST NAT Sante RECH MED8306
- Sanofi3990
- Pasteur Institut3426
- Agronomique INST NAT RECH1335
- Cellectis1320
- PF Medicament1204
- Commissariat Energie Atomique1156
Common questions
How many Life Sciences companies are there in France?
Radar tracks 1400 indexable Life Sciences companies headquartered in France that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in France?
The Life Sciences companies in France on this list have raised a combined $11.8B in disclosed equity funding across 495 funded companies.
Which is the highest-funded Life Sciences company in France?
Inventiva Pharma is the highest-funded Life Sciences company in France, with $433.2M in disclosed equity funding.
How many Life Sciences companies in France are funded?
495 of the 1400 Life Sciences companies in France on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in France?
1 Life Sciences company in France on this list is valued at $1B or more.
Who are the top investors in France Life Sciences companies?
The most active investors in France Life Sciences companies on this list include Bpifrance, Europa, EIC Fund, Sofinnova Partners, Idinvest Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.